RT-qPCR and RT-Digital PCR: a Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukaemia

Tyrosine Kinase Inhibitors (TKIs) are part of the successful clinical management of patients with Chronic Myeloid Leukaemia (CML). However, optimal clinical management of CML requires a robust, standardized laboratory assay used at key clinical milestones to ensure a successful outcome for patients on TKIs. Quantitative monitoring of %BCR-ABL1IS by reverse transcription quantitative PCR (RT-qPCR) is the gold standard strategy for evaluating patient repose to therapy and classification into prognostic subgroups.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Mary Alikian, Alexandra Whale, Susanna Akiki, Kim Piechocki, Celia Torrado, Thet Myint, Simon Cowen, Michael Griffiths, Jane Apperley, Helen White, Jim F. Huggett, Letizia Foroni Source Type: research